Signaling Cascades Determining Cell Fate in a Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$35,000
Active Dates
July 01, 2002 - June 30, 2003
Grant ID
G2002011
Summary
The precise pathogenic mechanisms that lead to retinal ganglion cell (RGC) death in glaucoma is unknown. Despite the vulnerability of RGCs in glaucoma, glial cells located in the optic nerve head, or retina, survive glaucomatous stress. Dr. Tezel has hypothesized that this different susceptibility to damage is due to differential activity of signaling cascades in these cell types. To determine the validity of this hypothesis, he is conducting in vitro cell culture experiments with each cell type separately and in co-culture to examine the signaling cascades in response to elevated hydrostatic pressure. He will also determine the activation of specific kinases in an in vivo rat model of high-pressure glaucoma, and in human donor eyes affected by glaucoma. It is hoped that the information gained from these studies will help describe the mechanisms determining the fate of cells in response to glaucoma, and may provide targets for possible new drugs to treat the condition.
Related Grants
National Glaucoma Research
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
Developing New Drugs for Glaucoma
Active Dates
January 01, 2026 - December 31, 2027
Principal Investigator
Pete Williams, PhD
Current Organization
Karolinska Institutet
National Glaucoma Research
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
Assessment of Vascular Resistance in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Brad Fortune, OD, PhD
Current Organization
Legacy Devers Eye Institute
National Glaucoma Research
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear
Interleukin-10 As a Neuroprotective Factor in Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Tatjana Jakobs, MD
Current Organization
The Schepens Eye Research Institute, Mass. Eye and Ear